network member

Vanderbilt-Ingram Cancer Center

691 Preston Building Nashville, TN 37232
Vanderbilt-Ingram Cancer Center

About Network Member

Vanderbilt-Ingram Cancer Center provides compassionate care, evidence-based prevention, pioneering research, community engagement and survivorship support. Designated a Comprehensive Cancer Center by the National Cancer Institute and a member of the National Comprehensive Cancer Network, Vanderbilt-Ingram is at the forefront of discovery. Our teams of scientists and clinicians are defining personalized care with immunotherapies, targeted treatments, precision radiation-oncology, innovative surgeries, and novel imaging technologies. Website: Vanderbilt-Ingram Cancer Center
800-811-8480
Enrollment Closed

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)
Cancer areas:Bladder
Froedtert & the Medical College of Wisconsin
John Theurer Cancer Center at Hackensack Meridian Health
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Rochester Medical Center - Wilmot Cancer Institute
Vanderbilt-Ingram Cancer Center
Virginia Commonwealth University
Currently Enrolling

TBCRC046

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)
Cancer areas:Breast
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Research Center
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Penn Medicine Abramson Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
University of Alabama at Birmingham Comprehensive Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Enrollment Closed

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Rutgers Cancer Institute of New Jersey
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center
Enrollment Closed

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Cancer areas:Breast
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
UPMC Hillman Cancer Center
Vanderbilt-Ingram Cancer Center